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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA), is associated with high morbidity
and mortality rates with rapid development of resistance.
Methods: A total of 512 MRSA isolates were procured from 6 major hospitals in Riyadh, Saudi
Arabia and antibiotic susceptibilities and MICs were documented against several antibiotics and
vancomycin. SPSS version 10 was used for statistical analysis.
Results: The prevalence of MRSA in the study hospitals ranged from 12% to 49.4%. Mean patient
age was 44 years with males constituting 64.4% and females 35.6%. Approximately 41.5% of the
isolates came from patients in the extreme age groups. MIC for vancomycin was in the susceptible
range for all isolates ranging from 0.25 to 3 ug/ml. The overall susceptibility of MRSA to the various
antibiotics tested was: fusidic acid 4.3%, sulfamethoxazole/trimethoprim 33.8%, gentamicin 39.6%,
mupirocin 77.0%, gatifloxacin 78.9%, chloramphenicl 80.7%, linezolid 95.1%, quinupristin/
dalfopristin 100%. Some differences were noted in the resistance of isolates among the participating
hospitals reflecting antibiotic usage. On the whole, inpatient isolates (accounting for 77.5% of the
isolates) were more resistant than outpatient isolates (22.5%) except for linezolid. Quinupristin-
dalfopristin and linezolid are the most effective antibiotics tested against inpatient isolates while
quinupristin-dalfopristin and gatifloxacin seem to be the most effective against outpatient isolates.
Approximately one forth of the isolates are no longer susceptible to mupirocin used for eradication
of the carrier state reflecting resistance developing after widespread use. Trends over time show
a tendency towards decreased susceptibility to gatifloxacin and linezolid with increasing
susceptibility to gentamicin and sulfamethoxazole/trimethoprim.
Conclusion: Quinupristin/dalfopristin and linezolid are two valuable additions to our antimicrobial
armamentarium, but resistance has already been described. To preserve their value, their use
should be limited to those rare cases where they are clearly needed. Fusidic acid, the local
antibiotic, gentamicin and trimethoprim/sulfamethoxazole should not be relied upon for treatment
of MRSA infections, at least empirically as the percentage of susceptible isolates is very low.
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Background
Staphylococcus aureus (S. aureus) is a major pathogen asso-
ciated with serious community- and hospital-acquired
diseases. Most of S. aureus infections are caused by methi-
cillin sensitive Staphylococcus aureus strains (MSSA) that
are susceptible to all other classes of anti-staphylococcal
antibiotics. Methicillin resistant Staphylococcus aureus
strains (MRSA) are implicated in serious infections and
nosocomial outbreaks. These strains show resistance to a
wide range of antibiotics, thus limiting the treatment
options to very few agents such as vancomycin and teico-
planin[1,2].
Microbes have genetic plasticity, which means that they
have the capacity to evolve in response to their environ-
ment. The major impetus for developing resistance is
selective pressure resulting from antibiotic use. The bacte-
ria that survive are those that develop mechanisms to
avoid being killed by antibiotics. The treatment of several
pathogens, including MRSA, is problematic. New solu-
tions are needed to preserve the activity of our current
antibiotic armamentarium, to lower the overall risk of
bacterial resistance and to successfully treat patients with
resistant bacterial infections. Options include: develop-
ment of new antibiotics to treat resistant organisms; vacci-
nation to prevent infections; and improved use of
antibiotics. Because bacteria will eventually develop
means to avoid being killed by antibiotics, judicious use
of antibiotics by all clinicians is imperative. Appropriate
antibiotic use involves selection of a "targeted spectrum"
antibiotic, as well as an appropriate dose and duration.
This entails updated databases on the antibiotic suscepti-
bility of such databases to new as well as traditional anti-
biotics[3].
Because the mechanism of resistance is an alteration in
the target of the antibiotic, MRSA are resistant clinically to
all beta-lactam antibiotics, even though a drug such as
cefazolin may appear to be active in vitro. It is also impor-
tant to note that MRSA are often multidrug-resistant and
are resistant to antibiotics such as the macrolides and
aminoglycosides, even though the mechanisms of action
of these antibiotics are different than that of the beta
lactams.
Clinical isolates of MRSA that are intermediate to vanco-
mycin, called vancomycin-intermediate Staphylococcus
aureus (VISA), were first identified in patients in Japan in
1996[4]. As of June 2002, 8 VISA infections had been doc-
umented in patients in the US[5]. Vancomycin has a nar-
row spectrum of activity, restricted to most Gram-positive
bacteria, and is the drug of choice for the treatment of
(MRSA). The vancomycin MIC for MRSA is 1–2 mg/L for
fully vancomycin-susceptible strains. Vancomycin inhib-
its peptidoglycan synthesis by binding to the D-Ala-D-Ala
terminus of the nascent murein monomer, resulting in the
inhibition of cell-wall synthesis. Only 50% of the vanco-
mycin arriving at the surface of a staphylococcus will
reach the target site. VISA are characterized by a thicker
cell-wall with increased amounts of peptidoglycan, and
the increased quantities of unprocessed D-Ala-D-Ala
cause increased 'trapping' and 'clogging', resulting in
higher vancomycin MICs of 8–16 µg/ml and the increased
inoculum effect observed with VISA in comparison with
fully vancomycin-susceptible strains[6].
In June 2002 the first clinical isolate of vancomycin resist-
ant  Staphylococcus aureus (VRSA) was reported from a
patient in Michigan[5]. The term VRSA is based on the
vancomycin breakpoint of the British Society for Chemo-
therapy, where a strain for which the MIC is 8 mg/liter is
defined as resistant. Since the same MIC is defined as indi-
cating intermediate susceptibility by the NCCLS, these
VRSA strains are called vancomycin-intermediate Staphylo-
coccus aureus or glycopeptide-intermediate Staphylococcus
aureus in the United States[7].
Early observations from both clinical isolates and labora-
tory-derived strains of GISA have focused on the bacterial
cell wall, where the glycopeptides exert their antimicrobial
effect. The glycopeptides prevent the transglycosylation
and transpeptidation reactions necessary for the forma-
tion of mature cell wall in Gram positive bacteria. Specif-
ically, they bind to the D-alanyl-D-alanine terminus of the
N-acetylmuramyl pentapeptide subunit of the nascent cell
wall. On the basis of these and other observations, Sier-
adzki et al. (1999)[8], proposed a functional model in
which glycopeptide molecules are first "captured" in the
cell wall, then serve to block access of other glycopeptide
molecules to nascent cell wall elements. Additional inves-
tigation of laboratory derived vancomycin-resistant
strains demonstrated down-regulation of certain penicil-
lin-binding proteins, including PBP2A.
Quinupristin/dalfopristin (Synercid) is a semisynthetic
antibiotic that combines two streptogramin compounds
in a 30:70 ratio, quinupristin (a group B streptogramin)
and dalfopristin (a group A streptogramin), and is the first
licensed antibiotic in its class. It inhibits bacterial protein
synthesis by binding of each component to a different site
on the 50S subunit of the bacterial ribosome, dalfopristin
leading to a conformational change in the ribosome
which increases the affinity of the ribosome for quinupris-
tin. Each of the two streptogramins separately acts as a
bacteriostatic agent but in combination they are bacteri-
cidal.
Quinupristin/dalfopristin is available only as an intrave-
nous product. Its spectrum of activity is similar to that of
vancomycin, with excellent activity against Gram positiveAnnals of Clinical Microbiology and Antimicrobials 2006, 5:30 http://www.ann-clinmicrob.com/content/5/1/30
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pathogens, including many resistant strains, such as
MRSA[9]. Its major value is that it provides a therapeutic
option for infections caused by vancomycin-resistant
Enterococcus faecium, VISA or VRSA. Unfortunately there
are already reports of VRE and MRSA resistant to quinu-
pristin/dalfopristin since its licensure in 1999[10,11].
Linezolid (Zyvox) is the first licensed oxazolidinone anti-
biotic. The oxazolidinones, synthetic compounds unre-
lated to other antimicrobials, inhibit bacterial protein
synthesis by binding to the ribosome 50S subunit, thus
blocking the initiation complex formation. Linezolid has
limited activity against selected Gram-negatives and
anaerobes but is highly active against Gram-positive bac-
teria, including resistant strains. Like quinupristin/dalfo-
pristin, linezolid is active against MRSA, but is only
bacteriostatic. Linezolid is available in both intravenous
and oral preparations and is 100% bioavailable after oral
administration. As such it provides an oral therapeutic
option for patients with Gram-positive infections resistant
to other oral antibiotics. Linezolid lacks cross-resistance to
any other group of antibiotics. Since linezolid became
available in 2000, clinical isolates of VRE and MRSA resist-
ant to linezolid have been reported from treated patients
[12-14].
Although the fluoroquinolones are not new antibiotics,
many studies are still being conducted to assess their uses.
Important features of this drug class include excellent bio-
availability after oral administration, achievement of high
tissue concentrations and a broad spectrum of activity. In
general fluoroquinolones are active against many Gram-
positive bacteria. They do not appear to be affected by β-
lactamase enzymes or altered penicillin binding proteins.
The quinolones have a unique mechanism of action; they
inhibit two bacterial enzymes, DNA gyrase and topoi-
somerase IV, that are essential for bacterial DNA synthesis.
Because they target bacterial sites distinct from the site of
action of other antibiotics, it was hypothesized by some
that resistance might be less likely to occur or slower to
develop[15]. Unfortunately these hopes were not borne
out.
Mupirocin is a naturally occurring agent produced by
Pseudomonas fluorescens and has successfully been used to
reduce substantially the nasal and hand carriage of
MRSA[16,17]. This regimen is least effective in patients
with either indwelling catheters or lesions on their skin.
Mupirocin (pseudomonic acid) specifically binds to bac-
terial isoleucyl-tRNA synthetase (IRS) and inhibits protein
synthesis[18]. However, emergence of mupirocin-resist-
ant MRSA strains as a result of long-term and intermittent
usage of the antibiotic has also been reported[19,20].
Repeated courses of topical antimicrobial treatment
should be discouraged as they often lead to emergence of
strains of bacteria that are resistant to these agents[21].
However, Fawley et al[22], 2006 provide evidence that
short-term mupirocin prophylaxis may be helpful in the
prevention of S. aureus surgical site infections with little
chance of risk of resistance selection.
Extensive anecdotal data support the use of trimethoprim/
sulfamethoxazole for infections caused by MRSA, but only
one randomized clinical trial has demonstrated its efficacy
for such infections[23].
A detailed knowledge of the susceptibility to antimicro-
bial agents is necessary to facilitate the development of
effective strategies to combat the growing problem of
resistance. A nationwide knowledge base is also impor-
tant for optimal patient management, control of nosoco-
mial infection and for the conservation of antibiotics. This
study was thus designed to track the resistance trends of
MRSA isolates from different hospitals to the non-beta-
lactams that are commonly used to combat infections by
it.
Methods
Five hundred and twelve MRSA isolates were consecu-
tively procured from samples submitted to the microbiol-
ogy labs from patients being treated in several tertiary care
hospitals with different geographical locations within Riy-
adh. The hospitals were designated the code names Hos-
pitals A to F. The names of the hospitals were not stated
for privacy reasons and are available from the authors
upon request. Isolates were collected during the period
from January 2004 through December 2005. No duplicate
isolates from the same patient and no environmental
strains were included in this study. The methicillin resist-
ant S. aureus ATCC 33591 was included as a reference
strain for quality control. Isolates were identified as S.
aureus  by the standard microbiological procedures[24].
Then the following tests were carried out:
I- Detection of methicillin resistance
This was carried out according to NCCLS guidelines using
Oxacillin agar screen test whereby all MRSA isolates were
spot inoculated onto Mueller-Hinton agar supplemented
with 6 µg/ml oxacillin and 4% NaCl, from a 0.5 McFar-
land standard suspension. The plates were incubated at
35°C for 24 h as recommended by the Clinical Laboratory
Standards Institute (CLSI), formerly NCCLS. If any growth
(more than one colony) was detected, the isolate was con-
sidered oxacillin or methicillin resistant[25].
II- Surveillance of MRSA with decreased vancomycin 
susceptibility
Vancomycin resistance was tested for by vancomycin agar
screening test whereby MRSA isolates were spot inocu-
lated onto Mueller Hinton agar supplemented with 6 µg/Annals of Clinical Microbiology and Antimicrobials 2006, 5:30 http://www.ann-clinmicrob.com/content/5/1/30
Page 4 of 11
(page number not for citation purposes)
ml of vancomycin from a 0.5 McFarland standard suspen-
sion. The plates were incubated at 35°C for 24 h as recom-
mended by the NCCLS. Any isolates growing two or more
colonies on this agar would be considered as positive[25].
III- Evaluation of Antibiotic susceptibility patterns
Various antibiotics including traditional as well as
recently introduced ones were used in disc diffusion tests
(Oxoid) according to NCCLS guidelines against all iso-
lates to determine the susceptibility of these isolates to
such antibiotics[25].
The antibiotics tested included: gatifloxacin, gentamicin,
linezolid, quinupristin-dalfopristin, mupirocin, fusidic
acid, chloramphenicol and trimethoprim-sulfamethoxa-
zole.
IV- MIC determination
Determination of the MIC against vancomycin to detect
any isolate with a decreased susceptibility to the drug
using E-test (AB-Biodisk, Solna, Sweden). The tests were
performed according to the manufacturer's instructions.
E-test for the other tested antimicrobials except fusidic
acid and chloramphenicol as well as E-test for minocy-
cline were performed for select susceptible strains of
MRSA to give an idea about the MIC in our tested isolates.
Statistical methods
Statistical package for social sciences (SPSS) version 10
was used to analyze our data. Comparison of categorical
variables and percentages between groups was done by
the Pearson chi-square test or Fisher's exact test, as appro-
priate. Logistic regression analysis was carried out to find
association between variables. The threshold for a signifi-
cant difference was designated a P value of <0.005. All
tests were two tailed.
Results and Discussion
MRSA isolates from inpatients accounted for 77.5% of the
isolates (397/512), while 22.5% came from outpatients
(115/512). Inpatient isolates were distributed in the fol-
lowing services: ICU: 96 (24.2%), Medicine: 59 (14.9%),
Surgery: 54 (13.6%), Pediatric: 48 (12.1%), Burn & Plastic
Surgery: 29 (7.3%), Orthopedic Surgery: 27 (6.8%),
Renal: 18 (4.5%) & other unspecified wards: 66 (16.6%).
Most isolates came from wounds (39.7%) followed by
soft tissues (28.4%).
Regarding the gender distribution of the isolates, 64.4%
were recovered from male patients while 35.6% were
from females. These values are quite similar to those
reported by van Belkum et al[26], 1997 from King Faisal
Specialist hospital – which was one of the hospitals
included in the present study – isolated from patients
referred to it from several other hospitals in Saudi Arabia.
They report procurement of 66% of their isolates from
male patients and 34% from females. Madani et al[27],
2001 also report a 65.8% recovery from males and 34.2%
from females in Saudi Arabia. Similarly, from the eastern
province of Saudi Arabia, Bukharie & Abdelhadi[28]
(2001) report 63% of MRSA isolation from males and
37% from females so this probably reflects the distribu-
tion of MRSA throughout the Kingdom with a male
patient predominance most likely due to the fact that
exposure is greater. This gender distribution was also sim-
ilar to that reported by Tentolouris et al[29], 2006 where
60.7% were males and 39.3% were females.
The mean age of the study group was 44 years with an age
span from <1 to 95 years old. This is higher than the mean
age reported by Bukharie & Abdelhadi (35.7y)[28].
Approximately 41.5% of the isolates came from patients
in the extreme age groups, 21.0% ≥ 60 years and 20.5% ≤
5 years. Madani et al[27], 2001 similarly report isolation
of 26.1% of MRSA from patients ≥ 60 years and 26.1%
from patients ≤ 1 year in another Saudi population. This
has likewise been reported by Kuehnert et al[30], 2005
from the USA whereby most MRSA diagnosis occurred in
persons ≥ 65 years of age. Discordantly, Tentolouris et
al[29], 2006 report a much higher mean age of 60.1 years.
The prevalence of MRSA among S. aureus isolates varied
from one hospital to another and ranged from 12% to
49.4% with 4 hospitals lying in the range of 27–33%.
Hospital A was the hospital from which the highest prev-
alence was encountered and this is expected due to the fact
of it being a referral hospital for most other Ministry of
Health hospitals within and around Riyadh. The 27–33%
range is quite similar to the 33% reported earlier from Jed-
dah, Saudi Arabia in 2001[27] and 2003[31], as well as
31% in 2005[32]. Yet others report the much lower prev-
alence of 12% in 2001 from the eastern province[28]. The
same prevalence is reported from Nigeria, Kenya and
Cameroon[33]. MRSA prevalence is generally reported to
be high in North America (43.7% & 43.2%)[30,34],
southern European countries[35,36], Japan (50–
70%)[37], Malaysia[38], Latin America[39], Ethiopia[40],
Sri Lanka[41]. In fact, according to the National Nosoco-
mial Infection Surveillance System (NNIS) report, 50% of
hospital acquired infections in ICUs in the USA are due to
MRSA[42]. In other countries such as Tunisia, Malta, Alge-
ria[33], Sweden, Switzerland, the Netherlands (the SEN-
TRY participants group, 2001)[43] and Australia
(14.9%)[44] on the other hand, it is low. In developing
countries, it has always been contended that the inappro-
priate use of antibiotics for community infections may
further increase the pressure to select MRSA and other
resistant bacteria. Yet the higher prevalence of MRSA
reported from other more developed countries argues
against this and perhaps points out to the fact that injudi-Annals of Clinical Microbiology and Antimicrobials 2006, 5:30 http://www.ann-clinmicrob.com/content/5/1/30
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cious use of antibiotics stands true not only for commu-
nity infections but is true for prescription as well as over
the counter medicines. Bacterial resistance threatens our
ability to treat both common and serious infections.
Although new antibiotics can effectively treat some resist-
ant pathogens and more research is needed to develop
novel antimicrobials, bacteria will eventually develop
resistance to any antibiotic with time. The misuse and
overuse of antibiotics drive the emergence and spread of
resistance. Eliminating inappropriate antibiotic use and
promoting more judicious use are essential parts of the
solution.
For all the acquired isolates, screening for oxacillin resist-
ance has been re-documented using the oxacillin agar
screening test using a Mueller-Hinton medium with 4%
NaCl and 6 µg/ml oxacillin according to NCCLS guide-
lines.
Similarly, screening for vancomycin resistance has been
carried out using Mueller Hinton agar plates plus 6 µg/ml
vancomycin. Until now, no such isolates have been
detected nor have they been reported by other researchers
in Saudi Arabian hospitals[28]. This is reassuring and
indicates that VRSA has not yet set foot in the Saudi hos-
pitals studied unlike reports from Japan[45], United
States[4], Europe and the Far East[46]. Results of the van-
comycin E-test showed that all isolates were susceptible
with MICs ranging from 0.25 µg/mL to 3 µg/mL, the
higher MICs mainly being from Hospital A.
Determining the in vitro activity of new antimicrobial
agents against pathogens showing increasing resistance to
other compounds is important when the global escalation
of this trend is considered. Hence the CLSI M39-A guide-
lines recommend that antibiogram data should be ana-
lyzed at least annually, thus determination of the
antibiotic susceptibility patterns of the procured isolates
against some non-β lactams was performed according to
the NCCLS guidelines and results of the susceptibility test-
ing are shown in table 1.
As depicted in table 1 and figure 1, 78.9% of the isolates
were susceptible to gatifloxacin (isolates with intermedi-
ate resistance were included with the resistant ones). This
is in contrast to the high resistance rates of MRSA isolates
from Japan to fluoroquinolones which are at the high 80–
95%[47], which probably reflects the excessive use of this
class of antibiotics there and thus induction of resistance.
In North America, gatifloxacin susceptibility is
64.7%[34], which is closer to our results. Susceptibility to
chloramphenical in the Japanese isolates ranged from
3.8% to 5.1%[47], while in the present study, 80.7% of
MRSA were susceptible. Panhotra et al, from Al-Hasa
region of Saudi Arabia report full susceptibility of their
MRSA isolates to chloramphenicol[48]. Linezolid was
highly effective in the present study with an overall 95.9%
susceptibility and was also reported in 2005 from Poland
and in 2006 from UK to be fully susceptible[49,50]. Iso-
lates showed a 77.0% susceptibility to mupirocin, this is
in between the 83.4% reported from Austria, Germany
and Switzerland[51], the 88.9% reported from the UK[22]
and the 71.9% reported from Kuwait[52]. Gentamicin
was poorly effective against our MRSA isolates (39.6%)
and gave even weaker results reported in 2001
(34.8%)[28], and 2005 (0% & 25%)[48,49]. Results given
by trimethoprim-sulfamethoxazole are even worse with a
mere 33.8% susceptibility in the current study, 21.1%
from Bukharie and Abdelhadi[28], 2001 and full resist-
ance by Panhotra et al, 2005[48]. Our results are in sharp
contrast with those of Echa'niz-Aviles et al[53], 2006 who
found all their isolates to be susceptible to gentamicin and
trimethoprim-sulphamethoxazole. It is pertinent to
deduce that antibiotics such as gentamicin and trimetho-
prim-sulfamethoxazole and the local fusidic acid should
no longer be relied upon at least for empirical treatment
of the local MRSA isolates. Whether the resistance
observed in tested isolates comes from their inherent
genetic propensity to acquire resistance or this is due to
mere selection of antibiotic resistant isolates through
monotherapy or under-dosage could not be clarified as
the previous antibiotic intake data were not available for
all isolates.
Table 1: Antibiotic susceptibility results of the tested isolates
Antibiotic Total susceptibility No. (%) (512) Inpatient isolates No. (%) (397) Outpatient isolates No. (%) (115)
Vancomycin 512(100) 397(100) 115(100)
Quinupristin/dalfopristin 512(100) 397(100) 115(100)
Linezolid 491(95.9) 386(97.2) 105(91.3)
Chloramphenicol 413(80.7) 302(76.1) 111(96.5)
Gatifloxacin 404(78.9) 299(75.3) 105(91.3)
Mupirocin 394(77.0) 292(73.6) 102(88.7)
Gentamicin 203(39.6) 118(29.7) 85(73.9)
Sulfamethoxazole/trimethoprim 173(33.8) 85(21.4) 88(76.5)
Fusidic acid 22(4.3) 15(3.8) 7(6.1)Annals of Clinical Microbiology and Antimicrobials 2006, 5:30 http://www.ann-clinmicrob.com/content/5/1/30
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Comparative susceptibility of the 512 MRSA isolates to tested antimicrobials Figure 1
Comparative susceptibility of the 512 MRSA isolates to tested antimicrobials.
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Table 1 also shows the percent susceptibilities of the
MRSA isolates from inpatients versus isolates from outpa-
tients. Susceptibilities of MRSA against all antibiotics
tested was higher for outpatient as opposed to inpatient
isolates except for linezolid. This was profoundly evident
for gentamicin and trimethoprim/sulfamethoxazole. It
was also evident for mupirocin, the local antibiotic used
for eradication of the carrier state which is expected due to
its use in the hospitals. This was also evident for gati-
floxacin, the fluoroquinolone, and again use of fluoroqui-
nolones and thus appearance of resistance against them is
expected in hospital isolates. It has been reported in the
The Medical Letter On Drugs and Therapeutics that in ade-
quate dosage, sulfamethoxazole/trimethoprim appears to
be effective against CA-MRSA, and that resistance is rare,
this was the case in the present study where 77.4% of the
outpatient isolates were susceptible to sulfamethoxazole/
trimethoprim while only 22.2% of the inpatient isolates
were susceptible to it.
While the collection of MRSA did not specifically deter-
mine community versus nosocomial isolates, it could be
generally expected that most outpatient isolates would be
community acquired while most inpatient isolates would
be nosocomial and thus we can deduce that hospital iso-
lates are more resistant than community isolates.
Table 2 shows the percentage susceptibilities of the iso-
lates from the different hospitals included in the study to
the antibiotics tested by the disc diffusion method. From
the table, wide variations are observed between the hospi-
tals regarding susceptibility to some antibiotics such as
gatifloxacin which was apparently effective for most hos-
pital isolates except for Hospital E where only 52.7% of
the isolates were susceptible and Hospital D where only
56.3 % of the isolates were susceptible. This difference
was statistically significant (p  < 0.005). This seems to
reflect a high usage of fluoroquinolones in these hospi-
tals. For quinupristin/dalfopristin, all of the hospital iso-Annals of Clinical Microbiology and Antimicrobials 2006, 5:30 http://www.ann-clinmicrob.com/content/5/1/30
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lates were 100% susceptible. The level of mupirocin
susceptibility was in the range of 71 to 88% for most of
the hospitals, which probably also reflects high usage as
an infection control measure. It has been shown previ-
ously that in hospitals where mupirocin use is common
the percentage of mupirocin resistant isolates can be
extremely high (63%)[54]. Surprisingly though, Caierao
et al[55], 2006 report an actual decrease in the level of
mupirocin resistance during regular use in ICU. Wide var-
iations in the susceptibility of isolates to sulfamethoxa-
zole/trimethoprim and gentamicin were observed among
hospitals, while susceptibility to chloramphenicol and
linezolid as well as resistance to fusidic acid were fairly
similar.
The antibiotic susceptibilities of the isolates were catego-
rized into patterns encompassing all the tested antimicro-
bials, table 3. The most common pattern observed was
that coded 1 (109/512, 21.3%) followed by pattern 16
(100/512, 19.5%) then patterns 9 (54/512, 10.5%) and 4
(49/512, 9.6%). This table could serve to delineate the
most probable pattern of the resistance per hospital thus
aiding in choice of empirical therapy.
The emergence of antimicrobial resistance among a
number of bacterial pathogens changes the way we prac-
tice medicine and places some of our patients at risk of
dying from their infections. The overuse and misuse of
antibiotics are major contributing factors to bacterial
resistance; therefore it is incumbent on each of us to use
antibiotics judiciously and appropriately. Judicious anti-
biotic use means that antibiotics are prescribed only when
indicated and that the drug chosen is the most narrow
spectrum agent that will be effective. Appropriate use
means choosing not only the correct antibiotic but also
the appropriate dose and duration, factors that can influ-
ence the development and carriage of resistant organ-
isms[56,57]. These "resistotype" data could be
complemented with "genotype" data and together, they
could be used to exchange profiles across borders rather
than actual material exchange.
The zone diameters of the isolates to the vancomycin discs
were determined and are displayed in figure 2. Zone
diameters ranged from 15 to 26 with most of the isolates
giving zones ranging from 16 to 19 mm. This is in compli-
ance with the CLSI standards for vancomycin (≤15 mm)
indicating that none of the isolates was resistant to vanco-
mycin. However, as the disc diffusion method would not
differentiate strains with reduced susceptibility to vanco-
mycin (MICs 4 to 8 µg/mL) from susceptible strains, the
MIC was determined using the E-test to test for the pres-
ence of any isolate with decreased susceptibility to the
antibiotic. The results of the vancomycin E-test for the iso-
lates are shown in figure 3. The histogram shows that all
isolates were susceptible to vancomycin with no evidence
of reduced susceptibility to the drug. The MICs fell in the
range of 0.25 to 3 µg/mL with most isolates in the 1 and
1.5 µg/mL groups.
The results of the E-test were as shown in figure 4 where
the line in between the two coloured areas of each box
represent the median or MIC50, the light area represents
isolates having MIC at the range between 50th percentile
and 75th percentile, while the dark area represents isolates
having MIC at the range between 50th percentile and 75th
percentile. Minocycline MIC ranged from 0.032 to 8 µg/
mL, meaning that all were susceptible except 3 isolates
which were intermediate (8 µg/mL). They showed 2
peaks, one at 0.094 – 0.125 µg/mL and the other at 2 – 3
µg/mL. Gatifloxacin MICs for susceptible strains ranged
from 0.016 to 4 µg/mL indicating that some isolates are in
the intermediate range (4 µg/mL). Most isolates had MICs
in the range of 0.064 – 0.094 µg/mL and 1.5 µg/mL. Gen-
tamicin MICs for susceptible isolates ranged from 0.047
to 4 µg/mL which are within the susceptible range by CLSI
≤ 4 µg/mL with most in the 0.035 to 0.5 µg/mL range. On
the other hand MICs for linezolid disc diffusion suscepti-
ble isolates ranged from 0.016 to 4 µg/mL which is within
the susceptible range according to CLSI standards (≤4 µg/
mL) with most isolates falling in the 0.5 µg/mL group. As
for mupirocin, MIC ranged from 0.064 to 6 µg/mL with
only one isolate giving 6 µg/mL. As susceptibility break-
Table 2: Percentage susceptibility of MRSA isolates from the studied hospitals to the antibiotics tested by disc diffusion according to 
CLSI standards
Hospital code FD GAT GEN LZD MUP Q/D SXT CHL
A (179) 3.4 84.9 36.1 97.8 74.3 100 20.1 68.7
B (72) 1.4 88.9 44.4 84.7 73.6 100 45.8 95.8
C (69) 2.9 87.0 68.1 92.8 88.4 100 66.7 91.3
D (64) 3.1 56.3 9.4 100 76.6 100 12.5 85.9
E (74) 9.5 52.7 29.7 94.6 71.6 100 31.1 71.6
F (54) 7.4 96.3 57.4 98.1 83.3 100 50 90.7
FD = fusidic acid, GAT = gatifloxacin, GEN = gentamicin, LZD = linezolid, MUP = mupirocin, Q/D = quinupristin/dalfopristin, SXT = 
sulfamethoxazole/trimethoprim, CHL = chloramphenicol.Annals of Clinical Microbiology and Antimicrobials 2006, 5:30 http://www.ann-clinmicrob.com/content/5/1/30
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points for mupirocin have not yet been established by
CLSI, the following widely accepted breakpoints were
used: ≤ 4 mg/l (susceptible), 8–128 mg/l (low-level resist-
ance) and ≥ 256 mg/l (high-level resistance)[55]. Thus
only one tested isolate showed decreased susceptibility
not mounting to low-level resistance and most of the
other isolates had MICs in the range of 0.064 to 0.094 µg/
mL. Similarly, MIC for Quinupristin-dalfopristin ranged
from 0.025 to 1 µg/mL which is also within the suscepti-
ble range (≤1 µg/mL) with most isolates in the 0.25–0.38
µg/mL range. Finally, trimethoprim/sulfamethoxazole
MIC ranged from 0.012 to 0.4 µg/mL, which is also much
lower than the CLSI standards for resistance (≥4/76 µg/
mL). There was no evident preponderance of any MIC
value.
In an attempt to study the antibiotic susceptibility trend
over time, the study isolates were segregated into 4 groups
according to the time of sample acquisition, each group
covering a period of 6 months of collection time. The
overall antibiotic susceptibility of each group to the tested
antimicrobials was tabulated in table 4. From the table, it
appears that the susceptibility to gatifloxacin markedly
declined over the studied intervals especially the forth
period (from 96.4% to 51.2%), this is not surprising,
given the reported rapid acquisition of MRSA to resistance
to fluoroquinolones. There was a trend towards declining
susceptibility to linezolid also (from 98.2% to 92.7%).
On the other hand, there was a trend towards increased
susceptibility to gentamicin which was quite remarkable
(14.5% to 46.3%) and a less evident one for sulfamethox-
azole/trimethoprim (21.8% to 39.0%). These probably
signify regaining some value of these antimicrobials with
decreased usage.
Thus, the good news is that bacterial resistance is to some
degree reversible. Reducing antibiotic use should be effec-
tive in combating resistance development, because resist-
ant bacteria have no competitive advantage in the absence
MIC of isolates to vancomycin as determined by the E-test Figure 3
MIC of isolates to vancomycin as determined by the 
E-test. The numbers above the columns are the MICs in µg/
mL.
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Table 3: Percent of the most common Antibiotic Susceptibility Patterns per hospital
Antibiotic Susceptibility Pattern A (179) B (72) C (69) D (64) E (74) F (54)
1 GAT/LZD/MUP/QD/CHL 22.3 33.3 15.9 29.7 4.1 24.5
2 GAT/LZD/QD 12.8 0 0 0 1.4 0
4 GAT/LZD/MUP/QD 12.8 4.2 4.3 9.4 16.2 4.1
9 LZD/MUP/QD/CHL 9.5 2.8 5.8 23.4 18.9 2.0
11 GAT/GEN/LZD/MUP/QD/C 11.2 0 1.5 0 0 8.2
16 GAT/GEN/LZD/MUP/QD/SXT/CHL 10.1 25 49.3 3.1 10.8 38.8
FD = fusidic acid, GAT = gatifloxacin, GEN = gentamicin, LZD = linezolid, MUP = mupirocin, Q/D = quinupristin/dalfopristin, SXT = 
sulfamethoxazole/trimethoprim, CHL = chloramphenicol. A-F represent the hospital codes
Zone diameters of the isolates against vancomycin disc Figure 2
Zone diameters of the isolates against vancomycin 
disc. The numbers above the columns are the diameters of 
the zones.
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of antibiotic exposure and because colonization with
resistant pathogens is usually transient. Because carriage
of these resistant bacteria resolves spontaneously, suscep-
tible strains eventually replace resistant strains in the
absence of antibiotic exposure. Antibiotic restrictions do
not always guarantee that antimicrobial resistance will
disappear, however, as demonstrated by a report from the
UK [58]. The reasons for this are not clear, although it may
be because the determinants of some antibiotic resistance
are genetically linked to other resistance determinants.
Conclusion
None of the 512 tested isolates had reduced susceptibility
to vancomycin with most MICs lying in the 1 – 1.5 range.
Linezolid and quinupristin-dalfopristin are the most
effective antibiotics tested against inpatient isolates while
gatifloxacin and quinupristin-dalfopristin seem to be the
most effective against outpatient isolates. Trends over
time show a tendency towards decreased susceptibility to
gatifloxacin and linezolid with increasing susceptibility to
gentamicin and sulfamethoxazole/trimethoprim.
Quinupristin/dalfopristin and linezolid are two valuable
additions to our antimicrobial armamentarium, but
resistance has already been described. To preserve their
value, their use should be limited to those rare cases where
they are clearly needed.
Differences noted in the susceptibility of the isolates from
different hospitals probably reflects the different patterns
of antibiotic usage and thus development of resistance in
these hospitals. Fusidic acid, the local antibiotic, gen-
tamicin and trimethoprim/sulfamethoxazole should not
be relied upon for treatment of MRSA infections, at least
empirically as the percentage of susceptible isolates is very
low. Approximately one forth of the isolates are no longer
susceptible to mupirocin used for eradication of the car-
rier state reflecting resistance developing after widespread
use. Keeping these resistotype data in mind while pre-
scribing antibiotics for MRSA infected patients should aid
in the prevention of its spread and abiding by the same
principles kingdom-wide could limit its deleterious
effects. An ongoing study by the same group is genotyping
these MRSA isolates for delineating their genetic origins
and perhaps their transmission dynamics as they consti-
tute a precious resource for further investigations.
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Table 4: Trend over time of percent antibiotic susceptibility according to collection period
Isolation period (No.) FD GAT GEN LZD MUP Q/D SXT CHL
1 (55) 3.6 96.4 14.5 98.2 85.5 100 21.8 83.6
2 (206) 3.4 88.3 36.9 98.1 80.6 100 30.6 72.3
3 (210) 5.2 83.8 51.4 93.8 75.6 100 36.2 82.3
4 (41) 4.8 51.2 46.3 92.7 82.9 100 39.0 82.9
FD = fusidic acid, GAT = gatifloxacin, GEN = gentamicin, LZD = linezolid, MUP = mupirocin, Q/D = quinupristin/dalfopristin, SXT = 
sulfamethoxazole/trimethoprim, CHL = chloramphenicol.
MICs for the tested antibiotics Figure 4
MICs for the tested antibiotics. VAN = vancomycin, MIN 
= minocycline, GAT = gatifloxacin, GEN = gentamicin, LZD 
= linezolid, MUP = mupirocin, Q/D = quinupristin/dalfopris-
tin, SXT = sulfamethoxazole/trimethoprim.
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